Sam Fazeli

I think maybe your other ambition should be to get a standing ovation when you present the data.

That's one of the things that companies seem to obviously enjoy.

Now, what's interesting, of course, is that PD-1 inhibitors, as you said, have not succeeded in small cell lung cancer.

PD-L1, which is not usually the story.

Usually PD-L1s tend to beat out the PD-L1 inhibitors.

And part of the argument is, although I've not really been able to 100% verify this, I don't think anybody can put their hand on their heart and say it's absolutely because the PD-1 inhibitor inhibits both PD-L1 and PD-L2.

And then, of course, in small cell lung cancer, Ticentric and Druvalumab, both of them have done better than PD-1s.

And yet you have a PD-1 here that seems to be doing fine.

So that's going to be interesting.

And it does seem to me that you don't want to go and take on the king, if you want to call it, Keytruda, but to go at it in a very measured way rather than going into non-small cell lung cancer, Keynote 181 head-to-head.

But I'm looking forward to that.

I did see the press release from Henleus.

In fact, my colleagues are thinking a little bit more about it.

And so maybe when we speak again, maybe at ESMO or just after ESMO, we can have a little bit more understanding of how that data is potentially going to look or what at least the bar is.

But we're very excited by that.

So congratulations on that news too.

Oh, thank you.

No, no, I'm really intrigued by this molecule, as you can tell.

The next one I thought we could touch on is the CDK4-6.

Now, where would you put that?